Quarterly ResultAug 5, 2026, 06:11 AM
LivaNova Q2 Revenue $390.6M; Raises FY26 Revenue & EPS Guidance
AI Summary
LivaNova PLC reported strong second-quarter 2026 financial results, with revenue reaching $390.6 million, an increase of 10.8% year-over-year, and adjusted diluted EPS of $1.26. Following this performance, the company raised its full-year 2026 revenue guidance to 8-9% constant-currency growth and adjusted diluted EPS guidance to $4.30-$4.40. LivaNova also announced a long-term agreement with Thermo Fisher Scientific to secure critical oxygenator component supply and made several management appointments.
Key Highlights
- Raised full-year 2026 revenue guidance to 8-9% constant-currency growth.
- Raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40.
- Reported Q2 2026 revenue of $390.6 million, an increase of 10.8% YoY.
- Achieved Q2 2026 adjusted diluted EPS of $1.26.
- Entered a long-term agreement with Thermo Fisher Scientific for oxygenator component supply.
- Cardiopulmonary segment revenue increased 11.2% to $221.6 million.
- Neuromodulation segment revenue increased 10.1% to $166.9 million.
- Lowered full-year 2026 adjusted free cash flow guidance to $140 million-$160 million.
Price Impact
More from LIVN